Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research note issued on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($1.21) per share for the year, down from their prior forecast of ($1.02). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.56. The firm had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million.

Several other research firms have also weighed in on SPRY. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an "outperform" rating and a $40.00 target price on the stock. Leerink Partners lifted their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Monday, January 13th. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Raymond James lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a research note on Tuesday, January 14th. Finally, Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, ARS Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $31.00.

Remove Ads

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY traded down $0.14 during midday trading on Wednesday, reaching $12.49. 1,191,077 shares of the stock were exchanged, compared to its average volume of 1,074,219. ARS Pharmaceuticals has a 12 month low of $7.55 and a 12 month high of $18.51. The business has a 50-day simple moving average of $12.15 and a two-hundred day simple moving average of $13.08. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -24.49 and a beta of 1.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SPRY. Bernard Wealth Management Corp. bought a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at about $27,000. KLP Kapitalforvaltning AS acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter valued at approximately $73,000. BNP Paribas Financial Markets acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter valued at approximately $75,000. Ball & Co Wealth Management Inc. acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter valued at approximately $105,000. Finally, Compass Capital Corp MA ADV acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter worth approximately $106,000. Institutional investors own 68.16% of the company's stock.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the sale, the insider now directly owns 7,696 shares of the company's stock, valued at $107,744. The trade was a 56.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.31, for a total value of $615,500.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,589,359.26. This represents a 19.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 159,600 shares of company stock valued at $1,866,516 in the last quarter. 40.10% of the stock is currently owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.